Ophthalmology Contract Research Organization Market Report 2026

The ophthalmology contract research organization market size has grown strongly in recent years. It will grow from $2.97 billion in 2025 to $3.22 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing prevalence of ophthalmic diseases, rising R&D activity in vision care, expansion of clinical trial complexity, growing demand for specialized trial expertise, increased regulatory scrutiny.

The ophthalmology contract research organization market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing investment in gene and cell therapies for eye diseases, rising demand for real-world evidence studies, expansion of digital trial management platforms, growing focus on rare ophthalmic conditions, increasing globalization of clinical research. Major trends in the forecast period include increasing outsourcing of ophthalmic clinical trials, rising demand for specialized eye disease cro services, growing adoption of advanced imaging and diagnostics, expansion of global multi-center trials, enhanced focus on regulatory compliance support.

The rising prevalence of eye disorders is expected to drive the growth of the ophthalmology contract research organization (CRO) market going forward. Eye disorders encompass a broad range of conditions that impact the structure or function of the eye, potentially impairing vision or causing discomfort. The increasing prevalence of eye disorders is largely attributed to an aging population, as age-related conditions such as cataracts, glaucoma, macular degeneration, and diabetic retinopathy become more common with advancing age. Ophthalmology contract research organizations support the development of treatments for eye disorders by offering specialized clinical research services that accelerate the testing, approval, and commercialization of innovative ophthalmic therapies. For instance, in August 2024, according to the Welsh Government, a UK-based government agency, ophthalmology departments in Wales reported over 35,000 admissions in 2023-24, reflecting a 5.8% increase from the previous year. Therefore, the rising prevalence of eye disorders is propelling the growth of the ophthalmology CRO market.

Key companies operating in the ophthalmology CRO market are focusing on developing innovative solutions, such as integrated trial platforms, to streamline study execution and improve data management efficiency. Integrated trial platforms are comprehensive digital systems that manage all aspects of clinical trials, including patient recruitment, data capture, compliance, and reporting, enabling ophthalmology CROs to enhance operational efficiency, reduce errors, and accelerate therapy development. For instance, in September 2024, Lindus Health Limited, a UK-based biotechnology company, launched its All-in-One Ophthalmology CRO, featuring a proprietary integrated trial platform named Citrus. This platform unifies critical aspects of ophthalmology clinical trials, including patient recruitment, electronic data capture (EDC), eConsent, scheduling, and clinical trial management system (CTMS) functions. By consolidating these components into a single customizable digital ecosystem, Citrus improves operational efficiency, minimizes data errors, and ensures regulatory compliance throughout the study lifecycle.

In January 2024, Iuvo BioScience LLC, a US-based contract research organization specializing in ophthalmology, acquired Promedica International for an undisclosed amount. Through this acquisition, Iuvo BioScience aims to expand its ophthalmic clinical CRO capabilities by integrating Promedica International’s specialized expertise, creating a fully integrated platform that supports end-to-end ophthalmic research from preclinical studies through all phases of clinical development. Promedica International, a US-based CRO, provides clinical research services to the medical device, biotechnology, and pharmaceutical industries, with a strong focus on ophthalmology.

Major companies operating in the ophthalmology contract research organization market are IQVIA Holdings Inc, Eurofins Scientific SE, Syneos Health Inc, Charles River Laboratories International Inc, Parexel International Corporation, Fortrea Holdings Inc, Medpace Holdings Inc, PSI CRO AG, Worldwide Clinical Trials, The Emmes Company LLC, TFS HealthScience, QPS Holdings LLC, ProTrial Research Inc, Lexitas Pharma Services Inc, Covance Inc, Cliantha Research Limited, Iris Pharma, WuXi AppTec Co Ltd, ORA Inc, Novotech Health Holdings Pty Limited, SGS Life Sciences, ICON plc.

North America was the largest region in the ophthalmology contract research organization market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the ophthalmology contract research organization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ophthalmology contract research organization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the ophthalmology contract research organization market by increasing costs for imported diagnostic equipment, imaging devices, laboratory instruments, and specialized trial consumables. CRO operations in North America and Europe are most affected due to dependence on imported ophthalmic technologies, while Asia-Pacific faces cost pressures related to cross-border clinical trial logistics. These tariffs are increasing trial execution costs and lengthening study timelines. However, they are also promoting regional CRO expansion, local laboratory capacity development, and domestic sourcing of ophthalmic research tools.

The ophthalmology contract research organization market research report is one of a series of new reports that provides ophthalmology contract research organization market statistics, including ophthalmology contract research organization industry global market size, regional shares, competitors with a ophthalmology contract research organization market share, detailed ophthalmology contract research organization market segments, market trends and opportunities, and any further data you may need to thrive in the ophthalmology contract research organization industry. This ophthalmology contract research organization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An ophthalmology contract research organization (CRO) is a specialized service provider that supports pharmaceutical, biotechnology, and medical device companies in conducting research and clinical trials related to eye diseases and vision care. These CROs offer end-to-end services or support specific phases of ophthalmic drug, biologic, or device development, spanning preclinical studies, regulatory submissions, and post-marketing surveillance.

The primary service types in ophthalmology contract research organizations (CROs) include early phase development services, clinical research, laboratory services, and regulatory consulting services. Early phase development services involve initial research and testing to evaluate the safety, dosing, and preliminary effectiveness of new drugs and devices prior to advanced clinical trials. Therapies applied include traditional interventions, anti-inflammatory interventions (such as corticosteroids, non-steroidal anti-inflammatory drugs, and other anti-inflammatory agents), anti-oxidative interventions, and advanced therapeutic interventions. These services are utilized by end users including pharmaceutical and biopharmaceutical companies, medical device companies, and academic institutes.

The ophthalmology contract research organization market includes revenues earned by entities by providing services such as preclinical research, clinical trial management, regulatory affairs, data management and biostatistics, medical imaging and reading, post-marketing surveillance, and strategic consulting. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.